Journals / Haseki Tıp Bülteni / 2017 / Cilt: 55 - Sayı: 1

Investigation of Antimicrobial Activity of Tigecycline in Methicillin Resistant Staphylococci Isolated from Hospitalized Patients in Intensive Care Units

Yoğun Bakım Ünitelerinde Yatan Hastalardan Elde Edilen Metisilin Dirençli Stafilokok Suşlarında Tigesiklin Etkinliğinin Araştırılması

Pages
52–55
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Tigecycline can be an alternative to other drugs against infections caused by methicillin-resistant staphylococci.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: The aim of this study was to evaluate the in vitro antimicrobial efficacy of tigecycline in methicillin-resistant staphylococci isolated from patients hospitalized in intensive care units.
📊
Key Findings & Data:Methods:­We investigated methicillin-resistant staphylococci isolated from blood, wound, urine, catheter tips, endotacheal aspiration fluids (ETA), and sputum specimens of patients hospitalized in the coronary and surgical intensive care units at İstanbul University Cardiology Institute, between June 2014 and December 2015.
💡
Conclusion & Impact:Tigecycline can be an alternative to other drugs against infections caused by methicillin-resistant staphylococci.
🔬Design:Research Article
📍Scope:2014 Verileri
⚙️Variables:Domain Parameters

Abstract

Aim: The aim of this study was to evaluate the in vitro antimicrobial efficacy of tigecycline in methicillin-resistant staphylococci isolated from patients hospitalized in intensive care units. Methods:­We investigated methicillin-resistant staphylococci isolated from blood, wound, urine, catheter tips, endotacheal aspiration fluids (ETA), and sputum specimens of patients hospitalized in the coronary and surgical intensive care units at İstanbul University Cardiology Institute, between June 2014 and December 2015. All staphylococci were identified by the conventional methods and susceptibility testing was performed using Mueller-Hinton Agar by the Kirby-Bauer disc diffusion method. Results: Of 67 methicillin-resistant staphylococci, 37 (55.2%) were Staphylococcus aureus (MRSA) and 30 (44.8%) were coagulase negative staphylococci (MRCNS). MRSA were isolated from blood (20), wound (10), ETA (3), urine (2), catheter tips (1) and sputum (1). MRCNS were also identified in blood (20) and wound (10). All staphylococci were susceptible to tigecycline. Conclusion: In our study, tigecycline was effective against all methicillin resistant staphylococci. Tigecycline can be an alternative to other drugs against infections caused by methicillin-resistant staphylococci.

Özet

Amaç: Çalışmamızda yoğun bakım ünitelerinde yatan hastalardan izole edilen metisilin dirençli stafilokok suşlarında tigesiklinin in vitro aktivitesinin değerlendirilmesi amaçlandı.Yöntemler:­ Haziran 2014-Aralık 2015 tarihleri arasında İstanbul Üniversitesi Kardiyoloji Enstitüsü Koroner ve Cerrahi Yoğun Bakım Üniteleri'nde yatan hastaların kan, yara, idrar, kateter ucu, endotrakeal aspirasyon (ETA) ve balgam kültürlerinden izole edilen metisilin dirençli stafilokoklar incelendi. Stafilokokların identifikasyonu için konvansiyonel metodlar kullanıldı ve antibiyotik duyarlılık testleri Mueller Hinton Agar'ın Kirby-Bauer disk difüzyon yöntemi ile yapıldı.Bulgular: Altmış yedi metisilin dirençli stafilokok suşunun 37'si (%55,2) Staphylococcus aureus (MRSA) ve 30'u (%44,8) koagülaz negatif stafilokok (MRKNS) olarak tanımlandı. MRSA'ların 20'si kan, 10'u yara, üçü ETA, ikisi idrar, biri kateter ucu ve biri de balgamdan izole edildi. MRKNS'lerin 20'si kan ve 10'u yaradan izole edildi ve tigesikline direnç saptanmadı.Sonuç: Çalışmamızda metisilin dirençli stafilokok suşlarının tamamı tigesikline duyarlı bulundu. Tigesiklin, metisilin dirençli stafilokoklarla oluşan enfeksiyonlara karşı alternatif ilaç olarak kullanılabilir.

🔖

Cite This Article

KÜÇÜKATEŞ, E., GÜLTEKİN, N. (2017). Investigation of Antimicrobial Activity of Tigecycline in Methicillin Resistant Staphylococci Isolated from Hospitalized Patients in Intensive Care Units. Haseki Tıp Bülteni, Cilt: 55 - Sayı: 1, 52–55. https://ajindex.com/articles/267828

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Khalili H, Dashti-Khavidaki S, Khaleghi S, Maleki Z, Rasoolinejad M. Evaluation of tigecycline activity against methicillin-resistance Staphylococcus aureus isolated from biological samples. Iran J Pharm Res 2010;9:61-5
  2. Garza-Gonzales E, Dowzicky MJ. Changes in Staphylococcus aureus susceptibility across Latin America between 2004 and 2010. Braz J Infect Dis 2013;17:13-9
  3. Kaleem F, Usman J, Hassan A, Omair M, Khalid A, Uddin R. Sensitivity pattern of methicillin resistant Staphylococcus aureus isolated from patients admitted in a tertiary care hospital of Pakistan. Iran J Microbiol 2010;2:141-3
  4. Vincent JL. Nosocomial infections in adult intensive-care units. Lancet 2003;361:2068-77
  5. Warren DK, Kollef MH. Prevention of hospital infection. Microbes Infect 2005;7:268-74
  6. Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of infection in Intensive Care (EPIC) study. EPIC International Advisory Committee. JAMA 1995;274:639-44
  7. Cartolano GL, Cheron M, Benabid D, Leneveu M, Boisivon A; Association of Hospital Bacteriologists, Virologists and Hygiene Professionals. Methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to glycopeptides (GISA) in 63 French general hospitals. Clin Microbiol Infect 2004;10:448-51
  8. Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivate of minocycline (GAR-936). Antimicrob Agents Chemother 1999;43:738-44
  9. Garrison MW, Neumiller JJ, Seter SM. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisims. Clin Ther 2005;27:12-22
  10. Noksin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 2005;41:303-14
  11. Projan SJ. Preclinical pharmacologyof GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy 2000;20:219-23
  12. Zinner SH. Overwiev of antibiotic use and resistance: setting the stage for tigecycline. Clin Infect Dis 2005;41:289-92
  13. Lee SY, Kuti JL, Nicolau DP. Polymyxins: older antibiotics for a new threat. Conn Med 2006;70:25-8
  14. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing, 19 th informational supplements, 2009; M100-S19. Wayne, PA: Clinical and Laboratory Standards Institute, 2009
  15. Barsanti